Zolbetuximab
About
Therapy type: Immunotherapy
Therapy strategy: CLDN18.2 inhibition
Mappings
NCI Thesaurus: Zolbetuximab (ncit:C85475)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CLDN18.2 >= 75%, HER2-negative | Adenocarcinoma of the Gastroesophageal Junction | Fluorouracil, Oxaliplatin, Zolbetuximab | |
| Sensitivity (+) | CLDN18.2 >= 75%, HER2-negative | Adenocarcinoma of the Gastroesophageal Junction | Capecitabine, Oxaliplatin, Zolbetuximab | |
| Sensitivity (+) | CLDN18.2 >= 75%, HER2-negative | Adenocarcinoma of the Gastroesophageal Junction | Capecitabine, Oxaliplatin, Zolbetuximab | |
| Sensitivity (+) | CLDN18.2 >= 75%, HER2-negative | Adenocarcinoma of the Gastroesophageal Junction | Fluorouracil, Oxaliplatin, Zolbetuximab |